Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926611 · ClinicalTrials.gov registry record · Phase 2
This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 311
- Enrollment target
NCT03926611 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 311 participants.
The verdict
NCT03926611, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 311 participants
- Enrollment target
Study Summary
This was a multicenter, randomized, double-blind and placebo-controlled phase 2b dose-finding study to assess the efficacy and safety of LOU064 in adults chronic spontaneous urticaria (CSU) patients inadequately controlled by H1-antihistamines
Interventions
- DRUG LOU064 Arm 1
- DRUG LOU064 Arm 2
- DRUG LOU064 Arm 3
- DRUG LOU064 Arm 4
- DRUG LOU064 Arm 5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2021-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926611
The ClinicalTrials.gov registry entry for NCT03926611 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which LOU064 Arm 1 is the first listed.
NCT03926611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03926611 about?
NCT03926611 is a clinical study titled "This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines". This was a multicenter, randomized, double-blind and placebo-controlled phase 2b dose-finding study to assess the efficacy and safety of LOU064 in adults chronic spontaneous urticaria (CSU) patients inadequately controlled by H1-antihistamines
What is the current status of trial NCT03926611?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 311 participants. The study started on 2019-06-06. Estimated completion is 2021-04-15.
What interventions are being tested in trial NCT03926611?
The interventions under investigation include: LOU064 Arm 1 (DRUG), LOU064 Arm 2 (DRUG), LOU064 Arm 3 (DRUG), LOU064 Arm 4 (DRUG), LOU064 Arm 5 (DRUG).
Who is sponsoring clinical trial NCT03926611?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.